Skip to main content

Intradetrusor OnabotulinumtoxinA

Intradetrusor onabotulinumtoxinA (Botox) is an FDA-approved, cystoscopically administered treatment for overactive bladder (OAB) at 100 U and neurogenic detrusor overactivity (NDO) at 200 U in patients inadequately managed by or intolerant of anticholinergic medications.[1][2] It is also indicated for NDO in pediatric patients ≥ 5 years old, using a separate weight-based regimen.[1] First reported for urological use by Schurch and colleagues in 2000, it has since become an established minimally invasive treatment for lower urinary tract dysfunction, with contemporary single-center data continuing to confirm the durability of response in real-world practice.[3][10]

This page is the procedural counterpart to the Botulinum Toxin pharmacology hub, which holds the broader drug-class evidence (mechanism, off-label uses, head-to-head data, novel delivery systems). The 2024 AUA/SUFU OAB Guideline groups it with minimally invasive options alongside Sacral Neuromodulation and PTNS.[8]

Mechanism of Action​

OnabotulinumtoxinA exerts a dual efferent and afferent mechanism in the bladder:[4][5][6]

  • Efferent (motor) pathway — Cleaves SNAP-25, a SNARE complex protein, thereby blocking acetylcholine release from peripheral cholinergic terminals, reducing detrusor contractile activity. It also blocks ATP release from purinergic efferent nerves.[4][5]
  • Afferent (sensory) pathway — Reduces urothelial ATP release, decreases expression of capsaicin (TRPV1) and purinergic (P2X3) receptors on suburothelial sensory nerves, and reduces substance P and nerve growth factor levels. These observations support a sensory contribution to clinical benefit.[5][6]
  • Anti-inflammatory effects — Decreases mast cell activation, reduces vascular endothelial growth factor expression, and attenuates neuroinflammation in the bladder wall.[5][7]

These mechanisms help explain increased storage capacity and reduced urgency. Proposed sensory and inflammatory mechanisms should not be equated with proven central desensitization in patients.[6]

FDA-Approved Indications and Dosing​

IndicationDoseInjection SitesDilutionReferences
Idiopathic OAB (adults)100 U20 sites (0.5 mL each)100 U in 10 mL NS[1][8][14][15]
NDO (adults, SCI / MS)200 U30 sites (1 mL each)200 U in 30 mL NS[1][11][12]
NDO (pediatric ≥ 5 years)≥34 kg: 200 U; <34 kg: 6 U/kg20 sites, 0.5 mL each10 mL total; use label dilution table[1]

In the adult NDO pivotal program, 300 U offered no clinically relevant advantage over 200 U. In Ginsberg's trial, among those not catheterizing at baseline, CIC for retention began in 42% with 300 U, 35% with 200 U and 10% with placebo.[11][12][13]

Landmark Clinical Trials​

NDO — Pivotal Phase 3 Trials​

The two trials enrolled 275 (Cruz 2011) and 416 (Ginsberg 2012) participants. Both included SCI and MS; the pooled 310 SCI / 381 MS counts are diagnoses across trials, not separate trial populations:[11][12]

  • OnabotulinumtoxinA 200 U reduced UI episodes by 21.8/week vs 13.2/week for placebo at 6 weeks in Cruz's trial (p < 0.01).[12]
  • Maximum cystometric capacity (MCC) increased by 141 mL (200 U) vs placebo (p < 0.001).[13]
  • Maximum detrusor pressure (MDP) decreased by ~33 cm H₂O (p < 0.001).[13]
  • Median time to retreatment request: 256 days (200 U) vs 92 days (placebo).[11]
  • I-QOL scores improved significantly across all domains.[11][12]

OAB — Phase 3 Trial (2013)​

Nitti's 557-patient RCT was one of the pivotal OAB trials (its 2017 publication is a reprint, not a separate trial):[14][15]

  • OnabotulinumtoxinA 100 U reduced daily UI episodes by −2.65 vs −0.87 for placebo (p < 0.001).[15]

Injection Technique​

Pre-procedure[8][17][18][19]​

  • Measure post-void residual (PVR) — caution if PVR > 100–200 mL.
  • Counsel regarding risk of urinary retention and potential need for clean intermittent catheterization (CIC).
  • Confirm willingness and ability to perform CIC if needed.
  • The US label specifies non-aminoglycoside antibiotic prophylaxis 1–3 days before, on treatment day and 1–3 days afterward; follow the local antimicrobial protocol.[1]
  • Local anesthetic instillation can be used; drain and irrigate before injection.[17]

Procedure[9][17][18]​

  • Performed via rigid or flexible cystoscope in the office setting (preferred) or operating room.
  • Reconstitute onabotulinumtoxinA in 10 mL preservative-free normal saline for OAB 100 U or 30 mL for NDO 200 U.
  • Use a cystoscopic injection needle appropriate for detrusor injection; needle length is not the intended insertion depth.[9]
  • Inject into the detrusor muscle, distributing across the posterior and lateral bladder walls.
  • Spare the trigone (standard practice in pivotal trials, though some evidence suggests trigonal injection is safe).[9]
  • The labeled OAB template uses 20 sites. Reduced-site protocols are technique variations discussed in expert consensus; do not present 1–20 sites as one universally validated standard.[17]
  • For adult NDO, 30 sites at 1 mL each is the labeled template; pediatric dosing differs as above.[12]
  • Procedure duration: approximately 15 minutes.[18]

Post-procedure​

  • Follow-up at 7–14 days to assess for urinary retention.[18]
  • In non-catheterizing patients, reassess PVR as clinically appropriate through 12 weeks.[1]

Duration of Effect and Retreatment​

  • Onset of action: 1–2 weeks post-injection.[18]
  • Duration of effect: typically 4–10 months (median ~6–9 months for NDO; ~6 months for OAB).[16][18][20]
  • Retreatment interval: no sooner than 12 weeks; expert consensus recommends scheduling at 6-month intervals with the option to retreat earlier if symptoms return.[17][18]
  • Patients do not appear to become refractory to repeat injections over multiple cycles, though one retrospective study suggested possible declining duration after the 5th treatment cycle (from ~10 months to ~5.5 months).[16][21][22]
  • Across indications, the adult limit is 400 U per 3 months; pediatric limits differ. Units are formulation-specific.[1]

Efficacy Summary​

ParameterOAB (100 U)NDO (200 U)References
UI episode reduction−2.65/day vs −0.87 placebo−21.8/week vs −13.2 placebo[12][15]
Complete continence rate22.9% vs 6.5%43.6–57.4% (long-term)[15][16]
MCC increaseSignificant (p < 0.001)+141 mL vs placebo[13][15]
MDP decreaseSignificant−33 cm H₂O vs placebo[13]
Positive treatment benefit60.8% vs 29.2%Consistent across 4 years[15][16]
Median duration of effect~6 months≥ 9 months[16][20]

Adverse Effects​

The adverse effect profile is primarily localized to the lower urinary tract:[13][14][19][23]

Common

  • Urinary tract infection — in pooled OAB label trials, 18% versus 6% placebo within 12 weeks; definitions and follow-up differ across studies.[1] For NDO, the cited meta-analysis reported RR 1.47 (95% CI 1.29–1.67) versus placebo.[13][14][24]
  • Urinary retention / CIC — pooled OAB trials: 6.5% initiated CIC versus 0.4% placebo over the treatment cycle.[1] NDO risk depends on baseline catheterization and dose; see the non-catheterizing subgroup above rather than applying its percentage to all patients.[3][11][12][13][14]
  • Dysuria — common in OAB patients.[14]
  • Hematuria — RR 1.70 (95% CI 1.01–2.85).[13]

Less Common

  • Muscle weakness — RR 2.59 (95% CI 1.36–4.91), reflecting systemic spread of toxin.[13]
  • Transient body weakness.[19]

Male-Specific Considerations

In male patients with idiopathic OAB, treatment response was 62.3%, with urinary retention in 13%. A higher bladder outlet obstruction index predicted both lower response rates and higher complication rates.[25]

Comparison with Other Minimally Invasive Therapies​

The 2024 AUA/SUFU guideline supports selecting SNM, PTNS, or intradetrusor BTX through shared decision-making and permits minimally invasive therapy without requiring prior behavioral or medication trials (Expert Opinion). This does not imply equal efficacy or identical harms. The FDA-labeled OAB indication still specifies inadequate response to or intolerance of an anticholinergic; distinguish guideline options from product labeling and coverage requirements.[8][18][26]

ROSETTA is the key direct comparison with SNM. It randomized 386 women with refractory UUI and analyzed 364 for the primary outcome. It used 200 U, above the labeled idiopathic OAB dose, so its benefit/harms cannot be transferred unchanged to 100-U treatment.[38]

Six-month outcomeOnabotulinumtoxinA 200 USNM
Mean daily UUI reduction3.9 episodes3.3 episodes
Complete resolution, exploratory diary endpoint35/178 (20%)6/166 (4%)
UTI over six months35%11%

The primary between-group difference was 0.63 episode/day (95% CI 0.13–1.14): statistically significant, with uncertain clinical importance. The complete-resolution analysis required at least four monthly diaries and was exploratory. Greater symptom reduction came with more UTI and catheterization; it does not establish universal superiority.[38]

Systematic and network reviews combine different doses, populations, follow-up and outcome definitions; they should not be read as a definitive ranking of BTX, SNM and PTNS.[27][28] Older real-world cost estimates are setting- and year-specific, not current patient prices.[29]

Mixed incontinence — MUSA​

MUSA (JAMA 2025) randomized 150 women with bothersome stress and urgency incontinence despite conservative/medical treatment; 137 contributed to the primary analysis. At six months, UDI total-score change was −66.8 with onabotulinumtoxinA 100 U versus −84.9 with midurethral sling (difference 18.1; 95% CI −4.6 to 40.7; p = 0.12). The trial did not demonstrate Botox superiority; it was not an equivalence trial. By 12 months, 22.6% had received both treatments. Discuss the likelihood of treating both symptom components and the different procedural risks.[39]

Off-Label / Emerging Indications​

Interstitial Cystitis / Bladder Pain Syndrome​

The AUA guideline lists intradetrusor onabotulinumtoxinA as a treatment option for IC/BPS when other treatments have failed, though evidence is Grade C.[30] A meta-analysis of 12 RCTs demonstrated significant improvements in ICSI, ICPI, VAS pain scores, and daytime frequency, with small-to-medium effect sizes.[31] Injection sites vary across studies (trigonal vs lateral / posterior walls), and the true effect is difficult to determine given the dearth of placebo-controlled trials of BTX alone.[30]

Detrusor Sphincter Dyssynergia (DSD)​

Injection of onabotulinumtoxinA into the external urethral sphincter (not intradetrusor) has been used for SCI patients with DSD, though this remains unlicensed.[4][7][32]

Other Investigational Uses​

  • Dysfunctional voiding (non-neurogenic).[32]
  • Benign prostatic hyperplasia — meta-analyses show no benefit over placebo for LUTS.[32][33]
  • Chronic prostatitis / pelvic pain (intraprostatic injection — emerging data).[32]
  • Novel delivery systems including liposome-encapsulated and hydrogel intravesical instillation are under investigation as less invasive alternatives to cystoscopic injection.[32]

Contraindications and Special Populations​

Adult NLUTD care also requires attention to storage pressures, upper-tract risk and reliable emptying; see the NLUTD guideline.[23]

Absolute Contraindications[1][18][19]​

  • Active UTI at time of injection.
  • Urinary retention or PVR >200 mL without routine CIC.[1]
  • Known hypersensitivity to botulinum toxin or its components.

Relative Contraindications​

  • Elevated PVR (> 100–200 mL) — increased risk of retention.[8]
  • A workable catheterization plan is required if retention develops; resolve inability or unwillingness before treatment.[1]
  • Impaired bladder emptying.[30]

Anticoagulation / Antiplatelet Therapy​

Two retrospective studies (totaling > 1,400 injection episodes) found no clinically significant bleeding in patients on antithrombotic therapy. In a cohort of 400 patients with 1,059 treatments, zero cases of hematuria were reported despite 27.8% being on antithrombotics with no discontinuation.[34] A second study of 114 injection episodes on full-dose anticoagulation / antiplatelet therapy reported only 0.88% spontaneously resolving hematuria.[35] These observational cohorts support a low bleeding risk but do not establish that every antithrombotic should always continue. Individualize the plan with the prescriber and procedural protocol.[34][35]

Pregnancy​

A 29-year pharmacovigilance analysis identified 913 reported pregnancies across indications; the 0.7% major-defect estimate came from 1/152 prospectively reported live births, not all 913 reports. This observational denominator does not establish pregnancy safety. Most exposures (94.6%) occurred before conception or during the first trimester.[36] Data remain limited, however, and onabotulinumtoxinA is not formally recommended during pregnancy.[36][37]

Practical Pearls​

  • Office-based procedure is preferred over hospital / surgery center for OAB injections.[17]
  • Staff involvement from scheduling through post-procedure follow-up optimizes patient experience and retreatment compliance.[17]
  • Patients should be counseled that the procedure is temporary and requires repeat treatments — setting expectations early improves long-term adherence.[17]
  • It is reasonable to bypass antimuscarinics and proceed directly to BTX in patients who cannot take or do not wish to try oral medications.[8]
  • For NDO patients already performing CIC, the risk of urinary retention is less clinically significant.[11]
  • Cost-effectiveness analyses suggest onabotulinumtoxinA is cost-effective compared with best supportive care for both OAB and NDO.[29]

Videos​

Intradetrusor OnabotulinumtoxinA Injection Technique
SUFU (2025)

References​

1. AbbVie. BOTOX (onabotulinumtoxinA): US prescribing information. Current manufacturer label. Accessed September 11, 2026.

2. Nitti V, Haag-Molkenteller C, Kennelly M, et al. "Treatment of Neurogenic Detrusor Overactivity and Overactive Bladder With Botox (onabotulinumtoxinA): Development, Insights, and Impact." Medicine. 2023;102(S1):e32377. doi:10.1097/MD.0000000000032377

3. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

4. Lin YH, Chiang BJ, Liao CH. "Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders." Toxins. 2020;12(2):E129. doi:10.3390/toxins12020129

5. Jhang JF, Kuo HC. "Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action." Toxins. 2016;8(4):120. doi:10.3390/toxins8040120

6. Apostolidis A, Dasgupta P, Fowler CJ. "Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity." Eur Urol. 2006;49(4):644–650. doi:10.1016/j.eururo.2005.12.010

7. Kuo HC. "Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?" Toxins. 2022;14(7):498. doi:10.3390/toxins14070498

8. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11–20. doi:10.1097/JU.0000000000003985

9. Karsenty G, Baverstock R, Carlson K, et al. "Technical Aspects of Botulinum Toxin Type A Injection in the Bladder to Treat Urinary Incontinence: Reviewing the Procedure." Int J Clin Pract. 2014;68(6):731–742. doi:10.1111/ijcp.12360

10. Nakai C, Miwa K, Kitagawa Y, et al. "The Efficacy of Intradetrusor Onabotulinumtoxin A Injection for Refractory Overactive Bladder Syndrome — a Single-Center Prospective Study." J Clin Med. 2025;14(12):4151. doi:10.3390/jcm14124151

11. Ginsberg D, Gousse A, Keppenne V, et al. "Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity." J Urol. 2012;187(6):2131–2139. doi:10.1016/j.juro.2012.01.125

12. Cruz F, Herschorn S, Aliotta P, et al. "Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial." Eur Urol. 2011;60(4):742–750. doi:10.1016/j.eururo.2011.07.002

13. Cheng T, Shuang WB, Jia DD, et al. "Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." PLoS One. 2016;11(7):e0159307. doi:10.1371/journal.pone.0159307

14. Nitti VW, Dmochowski R, Herschorn S, et al. "OnabotulinumtoxinA for the Treatment of Patients With Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial." J Urol. 2017;197(2S):S216–S223. doi:10.1016/j.juro.2016.10.109

15. Nitti VW, Dmochowski R, Herschorn S, et al. "OnabotulinumtoxinA for the Treatment of Patients With Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial." J Urol. 2013;189(6):2186–2193. doi:10.1016/j.juro.2012.12.022

16. Rovner E, Kohan A, Chartier-Kastler E, et al. "Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment." J Urol. 2016;196(3):801–808. doi:10.1016/j.juro.2016.04.046

17. Eilber KS, Brucker BM, Pezzella A, et al. "Expert Opinions on Best Practices for Overactive Bladder Management With OnabotulinumtoxinA." Toxins. 2025;17(4):207. doi:10.3390/toxins17040207

18. Rovner E. "Chapter 6: Practical Aspects of Administration of OnabotulinumtoxinA." Neurourol Urodyn. 2014;33(Suppl 3):S32–S37. doi:10.1002/nau.22637

19. American College of Obstetricians and Gynecologists. "Committee Opinion No. 604: OnabotulinumtoxinA and the Bladder." Obstet Gynecol. 2014;123(6):1408–1411. doi:10.1097/01.AOG.0000450760.42077.a1

20. Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG. "Comparison of the Effectiveness of Repeated Injections of Onabotulinum Toxin A for Refractory Idiopathic Detrusor Overactivity: Analysis of an Open Label Extension of a Randomized Trial (The RELAX Study)." Neurourol Urodyn. 2017;36(4):1201–1207. doi:10.1002/nau.23095

21. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. "Botulinum Toxin Injections for Adults With Overactive Bladder Syndrome." Cochrane Database Syst Rev. 2011;(12):CD005493. doi:10.1002/14651858.CD005493.pub3

22. Chohan N, Hilton P, Brown K, Dixon L. "Efficacy and Duration of Response to Botulinum Neurotoxin A (OnabotulinumA) as a Treatment for Detrusor Overactivity in Women." Int Urogynecol J. 2015;26(11):1605–1612. doi:10.1007/s00192-015-2751-4

23. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

24. Wang CC, Chou EC, Chuang YC, et al. "Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan — a Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)." Toxins. 2021;13(12):911. doi:10.3390/toxins13120911

25. Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L, et al. "Treatment Response and Complications After Intradetrusor OnabotulinumtoxinA Injection in Male Patients With Idiopathic Overactive Bladder Syndrome." J Urol. 2020;203(2):392–397. doi:10.1097/JU.0000000000000525

26. Farag F, Sakalis VI, Arteaga SM, et al. "What Are the Short-Term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-Neurogenic Lower Urinary Tract Symptoms Guidelines Panel." Eur Urol. 2023;84(3):302–312. doi:10.1016/j.eururo.2023.05.014

27. Roman MP, Ciortea R, Doumouchtsis SK, et al. "Comparison of Different Treatment Outcomes for Refractory Overactive Bladder: A Systematic Review and Meta-Analysis." Toxins. 2025;17(10):479. doi:10.3390/toxins17100479

28. Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. "Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis." Toxins. 2020;12(2):E128. doi:10.3390/toxins12020128

29. Chughtai B, Clemens JQ, Thomas D, et al. "Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost." J Urol. 2020;203(1):179–184. doi:10.1097/JU.0000000000000462

30. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

31. Giannantoni A, Gubbiotti M, Bini V. "Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review With Meta-Analysis." Toxins. 2019;11(9):E510. doi:10.3390/toxins11090510

32. Jhang JF, Kuo HC. "Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction." Toxins. 2018;10(7):E260. doi:10.3390/toxins10070260

33. da Silva CM, Chancellor MB, Smith CP, Cruz F. "Use of Botulinum Toxin for Genitourinary Conditions: What Is the Evidence?" Toxicon. 2015;107(Pt A):141–147. doi:10.1016/j.toxicon.2015.07.333

34. El Issaoui M, Elissaoui S, Elmelund M, Klarskov N. "Bleeding Risk in Female Patients Undergoing Intravesical Injection of OnabotulinumtoxinA for Overactive Bladder: A Danish Retrospective Cohort Study." Int Urogynecol J. 2023;34(10):2581–2585. doi:10.1007/s00192-023-05579-1

35. Mensah EE, Toia B, Nguyen L, et al. "Intravesical OnabotulinumtoxinA Injections in Patients on Antiplatelet and Anticoagulation Therapy." Neurourol Urodyn. 2021;40(7):1829–1833. doi:10.1002/nau.24758

36. Brin MF, Kirby RS, Slavotinek A, et al. "Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update." Neurology. 2023;101(2):e103–e113. doi:10.1212/WNL.0000000000207375

37. Gulati K, Wagle Shukla A, Pandey S. "Is the Use of Botulinum Toxin Injection for Treating Neurological Disorders Safe During Pregnancy and Lactation?" Toxicon. 2025;266:108546. doi:10.1016/j.toxicon.2025.108546

38. Amundsen CL, Richter HE, Menefee SA, et al. "OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial." JAMA. 2016;316(13):1366–1374. doi:10.1001/jama.2016.14617. Full text.

39. Harvie HS, Menefee SA, Richter HE, et al. "Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial." JAMA. 2025;333(21):1887–1896. doi:10.1001/jama.2025.4682.